SCHEMBL4022868

SCHEMBL4022868

O=CC[C@@H]1C[C@]1(CCNC(=O)O)c1cccc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.39
SLC6A3 Q01959 2/20 0.39
HSD11B1 P28845 1/20 0.38
GRIN2B Q13224 1/20 0.36
HTR2C P28335 2/20 0.36
HTR2A P28223 1/20 0.36
HTR2B P41595 1/20 0.36
ALDH1A1 P00352 3/20 0.35
P2RX7 Q99572 1/20 0.35
CCKBR P32239 1/20 0.35
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
KCNA3 P22001 1/20 0.34
TAAR1 Q96RJ0 1/20 0.34
EPHX2 P34913 1/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
ICMT O60725 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4021859 1.00 SLC6A4 (0.39) SLC6A4SLC6A3HSD11B1GRIN2BHTR2C
SCHEMBL4021855 0.77 TACR3 (0.39) SLC6A4SLC6A3HSD11B1HTR2CHTR2A
SCHEMBL4022865 0.77 TACR3 (0.39) SLC6A4SLC6A3HSD11B1HTR2CHTR2A
SCHEMBL6172602 0.73 CCR2 (0.36) SLC6A4SLC6A3HSD11B1HTR2CHTR2A
SCHEMBL4020346 0.72 SLC6A4 (0.40) SLC6A4SLC6A3HTR2CP2RX7SLC6A2
SCHEMBL4020641 0.72 SLC6A4 (0.40) SLC6A4SLC6A3HTR2CP2RX7SLC6A2
SCHEMBL4022096 0.71 LMNA (0.38) SLC6A4P2RX7SLC6A2
SCHEMBL4025564 0.71 LMNA (0.38) SLC6A4P2RX7SLC6A2
SCHEMBL4023906 0.71 LMNA (0.38) SLC6A4P2RX7SLC6A2
SCHEMBL4019261 0.71 LMNA (0.38) SLC6A4P2RX7SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569579-B2 for inhibition of HIV replication and treatment of acquired immune deficiency syndrome SMITHKLINE BEECHAM CORPORATION (US) 2009-08-04 US disclosed
EP-1569934-B1 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2008-01-23 EP disclosed
US-20060052408-A1 Cyclopropyl compounds as ccr5 antagonists SMITHKLINE BEECHAM CORPORATION 2006-03-09 US disclosed
EP-1569934-A2 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-09-07 EP disclosed
WO-2004055010-A2 CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2004-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052408-A1 Cyclopropyl compounds as ccr5 antagonists CCR5, CCR1, CCL5 SLC6A4 1697/4885SLC6A3 1853/4885HSD11B1 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.